Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease
Many neurodegenerative diseases are characterized by progressive loss of neurons and abnormal protein accumulation, including amyloid (A)β and tau in Alzheimer’s disease and Lewy bodies and α-synuclein (α-syn) in Parkinson’s disease (PD). Recent evidence suggests that adaptive immunity plays an impo...
Main Authors: | Zhipeng Wang, Ge Gao, Chunli Duan, Hui Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-07-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332218377989 |
Similar Items
-
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
by: Darren J. Schofield, et al.
Published: (2019-12-01) -
Novel DNA Aptamers for Parkinson’s Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation
by: Yuan Zheng, et al.
Published: (2018-06-01) -
Mechanism of Anti-α-Synuclein Immunotherapy
by: Jun Sung Lee, et al.
Published: (2016-01-01) -
Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology
by: Nishant N. Vaikath, et al.
Published: (2015-07-01) -
Studies of α-synuclein Oligomers-with Relevance to Lewy Body Disorders
by: Fagerqvist, Therese
Published: (2013)